<DOC>
	<DOCNO>NCT02083484</DOCNO>
	<brief_summary>This expanded access program ( EAP ) participant progress prior systemic therapy include ipilimumab , V-raf murine sarcoma viral oncogene homolog B1 ( BRAF ) inhibitor mitogen-activated protein kinase ( MEK ) enzyme inhibitor indicate . Participants eligible participated pembrolizumab ( MK-3475 ) clinical trial exception participant enrol pembrolizumab protocol MK-3475-006 receive treatment ipilimumab treatment arm progress ; participant eligible participate EAP , regardless prior treatment BRAF/MEK inhibitor , long eligibility criterion MK-3475-030 met .</brief_summary>
	<brief_title>Program Pembrolizumab ( MK-3475 ) Participants With Metastatic Melanoma Who Have Failed Standard Care Therapy Including Ipilimumab ( MK-3475-030 )</brief_title>
	<detailed_description>Pembrolizumab approve U.S. Food Drug Administration treatment patient unresectable metastatic melanoma disease progression follow ipilimumab BRAF V600 mutation positive , BRAF inhibitor . The Expanded Access Program ( EAP ) medicine U.S. close . The EAP continue outside U.S .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>Inclusion criterion : Unresectable ( Stage III ) metastatic melanoma Failed progressed standard care systemic therapy include ipilimumab ( exception participant progressive disease ipilimumab arm MK3475006 , regardless prior treatment BRAF/MEK inhibitor , long eligibility criterion study meet ) Willing sign Informed Consent Eastern Cooperative Oncology Group Performance status 0 1 Female participant childbearing potential must willing use adequate contraception surgically sterile , abstain heterosexual activity start first dose treatment least 120 day last dose pembrolizumab Male participant must agree use adequate method contraception start first dose treatment 120 day last dose pembrolizumab Adequate organ function Exclusion criterion : Eligible accessible pembrolizumab clinical study previously participate pembrolizumab clinical study ( exception participant progressive disease ipilimumab arm MK3475006 ) Eligible treatment market BRAF inhibitor MEK inhibitor ( exception participant progressive disease ipilimumab arm MK3475006 , regardless prior treatment BRAF/MEK inhibitor , long eligibility criterion study meet ) Not recovered Common Terminology Criteria Adverse Events ( CTCAE ) Grade 1 good due prior chemotherapy , radioactive , biological cancer therapy ( include monoclonal antibody ) Not recover minor major surgery le 4 week major surgery History lifethreatening severe immunerelated adverse event treatment another immunotherapy Expected require form systemic antineoplastic therapy receive pembrolizumab History clinically severe autoimmune disease ( e.g. , require chronic immunosuppressive therapy ) History pneumonitis , organ transplant , human immunodeficiency virus ( HIV ) , active hepatitis B hepatitis C Active central nervous system metastasis , carcinomatous meningitis , untreated brain metastasis Pregnant breastfeeding , expect conceive father child within project duration treatment pembrolizumab Active infection require systemic therapy</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>